Taking two or more aspirin tablets a week can help reduce the risk of developing primary liver cancer, also called hepatocellular carcinoma (HCC), according to a research. The HCC is diagnosed at a late stage, leading to an average survival time of less than a year. It is considered the second leading cause of cancer deaths globally.
Researchers from the Massachusetts General Hospital in the US have found that regular aspirin use — taking two or more 325 mg tablets a week for five years or more — led to a to a 49 per cent reduced risk of developing HCC. In addition, among those taking aspirin for five years or more, the relative risk was reduced by 59 per cent.
For the study, appearing in the journal Jama Oncology, the team examined over 30 years of data on more than 1,70,000 participants who were asked whether they took aspirin on a regular basis — how many standard-dose (325 mg) tablets they took a week and for how long.